FDA Selects Aetion Evidence Platform® to Advance Regulatory Science and Innovation
Aetion announced that it is expanding its relationship with the U.S. Food and Drug Administration to use real-world evidence to study COVID-19 interventions and advance regulatory science and innovation. The FDA and Aetion will use the Aetion Evidence Platform, validated software that enables efficient, transparent, and reliable RWE research, to develop a framework and system of studies for the rapid assessment of COVID-19 inpatient medical products. The project is designed to demonstrate how using a platform-based approach furthers regulatory learnings on the use of RWE to...